Mounjaro, also known as tirzepatide, is a medication approved by the Food and Drug Administration (FDA) in 2022 to help control blood sugar in people with type 2 diabetes. It is given as an injection once a week. Moreover, this medication is the first and only approved medicine that activates GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors in the body.